T-cell prolymphocytic leukemia natural history, complications and prognosis: Difference between revisions
No edit summary |
No edit summary |
||
Line 7: | Line 7: | ||
== Natural History, Complications and Prognosis== | == Natural History, Complications and Prognosis== | ||
*The majority of patients with T-cell prolymphocytic leukemia are symptomatic at the time of diagnosis. | *The majority of [[Patient|patients]] with T-cell prolymphocytic leukemia are [[symptomatic]] at the time of diagnosis. | ||
*Early clinical features include [[fever]], [[fatigue]], and [[lymphadenopathy]]. | *Early clinical features include [[fever]], [[fatigue]], and [[lymphadenopathy]]. | ||
*If left untreated, patients with T-cell prolymphocytic leukemia may progress to develop [[multiple organ failure]]. | *If left untreated, patients with T-cell prolymphocytic leukemia may progress to develop [[multiple organ failure]]. | ||
Line 14: | Line 14: | ||
:*[[Infection|Infections]] | :*[[Infection|Infections]] | ||
:*[[Bleeding : Overview|Bleeding]] | :*[[Bleeding : Overview|Bleeding]] | ||
*[[Prognosis]] is generally poor, and the median survival time of patients with T-cell prolymphocytic leukemia is approximately one to two years.<ref name="pmid23382603">{{cite journal |vauthors=Graham RL, Cooper B, Krause JR |title=T-cell prolymphocytic leukemia |journal=Proc (Bayl Univ Med Cent) |volume=26 |issue=1 |pages=19–21 |year=2013 |pmid=23382603 |pmc=3523759 |doi= |url=}}</ref> | *[[Prognosis]] is generally poor, and the median survival time of patients with [[T cell|T-cell]] [[prolymphocytic leukemia]] is approximately one to two years.<ref name="pmid23382603">{{cite journal |vauthors=Graham RL, Cooper B, Krause JR |title=T-cell prolymphocytic leukemia |journal=Proc (Bayl Univ Med Cent) |volume=26 |issue=1 |pages=19–21 |year=2013 |pmid=23382603 |pmc=3523759 |doi= |url=}}</ref> | ||
*Patients with CD45RO+/CD45RA- immunophenotype tend to have a more indolent course. | *[[Patient|Patients]] with CD45RO+/CD45RA- [[immunophenotype]] tend to have a more indolent course. | ||
*It seems following factors are associated with worse prognosis: | *It seems following factors are associated with worse [[prognosis]]: | ||
**Increased expression of TCL1 | **Increased expression of [[TCL1A|TCL1]] | ||
**Increased activity of the serine-threonine kinase AKT | **Increased activity of the [[serine-threonine kinase]] [[AKT]] | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} |
Latest revision as of 13:09, 4 April 2019
T-cell prolymphocytic leukemia Microchapters |
Differentiating T-cell prolymphocytic leukemia historical perspective from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
T-cell prolymphocytic leukemia natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of T-cell prolymphocytic leukemia natural history, complications and prognosis |
FDA on T-cell prolymphocytic leukemia natural history, complications and prognosis |
CDC on T-cell prolymphocytic leukemia natural history, complications and prognosis |
T-cell prolymphocytic leukemia natural history, complications and prognosis in the news |
Blogs on T-cell prolymphocytic leukemia natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Qurrat-ul-ain Abid, M.D.[2], Maria Fernanda Villarreal, M.D. [3]
T-cell prolymphocytic leukemia Microchapters |
Differentiating T-cell Prolymphocytic Leukemia from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
T-cell prolymphocytic leukemia natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of T-cell prolymphocytic leukemia natural history, complications and prognosis |
FDA on T-cell prolymphocytic leukemia natural history, complications and prognosis |
CDC on T-cell prolymphocytic leukemia natural history, complications and prognosis |
T-cell prolymphocytic leukemia natural history, complications and prognosis in the news |
Blogs on T-cell prolymphocytic leukemia natural history, complications and prognosis |
Directions to Hospitals Treating T-cell prolymphocytic leukemia |
Overview
T-cell prolymphocytic leukemia is diagnosed after its symptoms appear. Failure to treat can result in multiple organ failure.
Natural History, Complications and Prognosis
- The majority of patients with T-cell prolymphocytic leukemia are symptomatic at the time of diagnosis.
- Early clinical features include fever, fatigue, and lymphadenopathy.
- If left untreated, patients with T-cell prolymphocytic leukemia may progress to develop multiple organ failure.
- Common complications of T-cell prolymphocytic leukemia, include:[1]
- Prognosis is generally poor, and the median survival time of patients with T-cell prolymphocytic leukemia is approximately one to two years.[1]
- Patients with CD45RO+/CD45RA- immunophenotype tend to have a more indolent course.
- It seems following factors are associated with worse prognosis:
- Increased expression of TCL1
- Increased activity of the serine-threonine kinase AKT